Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?Positive | ||
Negative | ||
Uncertain | ||
Constraining | ||
Legalese | ||
Litigous | ||
Readability |
H.S. sophomore Avg
|
New words:
Adagio, AI, AITI, albeit, allogeneic, allogenic, allograft, alvelstat, Anderson, Anne, antimicrobial, Aruna, Atlantic, azithromycin, Background, Bartholomew, BBI, BDO, bidder, biomedical, charity, Chorionic, CJEU, CLAD, Clinigen, CLN, closet, Commissioner, CTA, CTx, Cum, Darden, DAWN, deployed, Deputy, disagreement, Dysfuntion, East, Eastern, ELM, ence, engender, epidemic, Expiratory, explained, Fellow, fibrosing, fibrotic, fifty, follitropin, frame, front, Genmab, germ, Graduate, graduated, graft, GSK, HCG, HIV, humanised, Hyland, ID, idiopathic, immunosuppressive, inaccuracy, Incyte, Infinity, interoperability, intracytoplasmic, intrauterine, invaded, IO, Irish, Isopogen, itacitinib, Jackie, Jacquet, Jefferson, jointly, Krishnan, Kymab, lambda, Landscape, Laude, Lecturer, LifeSci, liposomal, LON, Magna, marrow, MD, melanoma, mesenchymal, microMolar, military, misuse, myeloperoxidase, NaN, NATO, Network, NIC, Opidivo, Osprey, overseen, overweight, Parkin, pathogenic, PAYE, Peak, pembrolizumab, Philosophy, Pierre, podium, provisional, PTE, Pune, QP, radding, Rainbow, recertification, recite, reclassification, representation, retaliatory, retransplant, Rubric, Russian, ruxolitinib, Scholar, Scotland, scrutinize, SCT, Sickle, squeeze, Suba, Summa, SZ, TCA, temporal, terminology, theEBT, tothe, Trinity, Ukraine, uveal, Vectura, Virginia, vitro, whatsoever, wider, Xspray, Zambon, ZZ
Removed:
abbvie, accruing, acting, Alexza, Allegro, alongside, Alpine, amounted, Andersen, Andriol, androgel, antagonist, approximate, Arthur, Avastin, Axiron, backlog, Blackburn, BMS, bore, borrowed, Celgene, Celstream, chemotherapeutic, circumvent, consequential, considerable, DCF, decided, Depository, disclaim, diversify, draft, entirety, Erbitux, expressly, extraterritorially, Fermenta, fining, Founder, gel, Genentech, internet, Invalidation, inventory, jatenzo, lender, Lipocine, merged, MiNA, minimal, mixture, multiplied, myopathy, nailing, notified, online, Paul, prepaid, PTC, quotation, release, Sosei, sputum, Squibb, sustained, Syngene, tlando, transdermally, transpire, travel, TRT, twelfth, understand, upcoming, web
Filing tables
Filing exhibits
- 20-F Annual report (foreign)
- 4.17 EX-4.17
- 4.26 EX-4.26
- 4.33 EX-4.33
- 4.34 EX-4.34
- 4.35 EX-4.35
- 4.36 EX-4.36
- 4.37 EX-4.37
- 4.38 EX-4.38
- 4.39 EX-4.39
- 4.40 EX-4.40
- 4.44 EX-4.44
- 4.45 EX-4.45
- 12.1 EX-12.1
- 12.2 EX-12.2
- 13.1 EX-13.1
- 13.2 EX-13.2
- 15.1 EX-15.1
- 15.2 EX-15.2
- 16.1 EX-16.1
- Download Excel data file
- View Excel data file
MREO similar filings
Filing view
External links
Exhibit 15.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
Mereo BioPharma Group plc
London, United Kingdom
We hereby consent to the incorporation by reference in the Registration Statements on Form F-3 (No. 333-249341 and No. 333-239708 and No. 333-258495) and Form S-8 (No. 333-231636 and No. 333-236498 and No. 333-252147 and No. 333-262151) of Mereo BioPharma Group plc of our report dated March 31, 2022, relating to the consolidated financial statements which appears in this Annual Report on Form 20-F.
/s/ BDO LLP
BDO LLP
Reading, United Kingdom
March 31, 2022